Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)

Active, not recruitingOBSERVATIONAL
Enrollment

858

Participants

Timeline

Start Date

April 6, 2018

Primary Completion Date

March 30, 2027

Study Completion Date

March 30, 2027

Conditions
Dermatitis, Atopic
Interventions
DRUG

Dupilumab

Dupixent 1 dose at Baseline required for eligibility; otherwise, no therapeutic intervention required during the course of the study. In addition to (or substituting for) DUPIXENT®, participants may receive marketed drugs as deemed necessary by their physicians for the treatment of AD or comorbid conditions.

Trial Locations (99)

10016

Regeneron Investigational Site, New York

10029

Regeneron Investigational Site, New York

10075

Regeneron Investigational Site, New York

10552

Regeneron Investigational Site, Mount Vernon

11030

Regeneron Investigational Site, Manhasset

11042

Regeneron Investigational Site, Lake Success

11374

Regeneron Investigational Site, Forest Hills

Regeneron Investigational Site, Kew Gardens

11501

Regeneron Investigational Site, Mineola

11530

Regeneron Investigational Site, Garden City

12180

Regeneron Investigational Site, Troy

18960

Regeneron Investigational Site, Sellersville

19067

Regeneron Investigational Site, Yardley

19107

Regeneron Investigational Site, Philadelphia

19140

Regeneron Investigational Site, Philadelphia

19422

Regeneron Investigational Site, Blue Bell

20772

Regeneron Investigational Site, Upper Marlboro

20850

Regeneron Investigational Site, Rockville

21162

Regeneron Investigational Site, White Marsh

21204

Regeneron Investigational Site, Towson

22204

Regeneron Investigational Site, Arlington

23502

Regeneron Investigational Site, Norfolk

28025

Regeneron Investigational Site, Concord

29425

Regeneron Investigational Site, Charleston

30152

Regeneron Investigational Site, Marietta

30328

Regeneron Investigational Site, Sandy Springs

31217

Regeneron Investigational Site, Macon

33063

Regeneron Investigational Site, Margate

33146

Regeneron Investigational Site, Coral Gables

33406

Regeneron Investigational Site, West Palm Beach

35205

Regeneron Investigational Site, Birmingham

40202

Regeneron Investigational Site, Louisville

40701

Regeneron Investigational Site, Corbin

43209

Regeneron Investigational Site, Bexley

43302

Regeneron Investigational Site, Marion

44333

Regeneron Investigational Site, Akron

45040

Regeneron Investigational Site, Mason

45701

Regeneron Investigational Site, Athens

46168

Regeneron Investigational Site, Plainfield

46804

Regeneron Investigational Site, Fort Wayne

48084

Regeneron Investigational Site, Troy

48088

Regeneron Investigational Site, Warren

48103

Regeneron Investigational Site, Ann Arbor

48706

Regeneron Investigational Site, Bay City

53226

Regeneron Investigational Site, Milwaukee

60077

Regeneron Investigational Site, Skokie

60526

Regeneron Investigational Site, La Grange Park

60654

Regeneron Investigational Site, Chicago

61820

Regeneron Investigational Site, Champaign

62604

Regeneron Investigational Site, Springfield

63110

Regeneron Investigational Site, St Louis

63501

Regeneron Investigational Site, Kirksville

66215

Regeneron Investigational Site, Overland Park

68505

Regeneron Investigational Site, Lincoln

74136

Regeneron Investigational Site, Tulsa

75231

Regeneron Investigational Site, Dallas

76051

Regeneron Investigational Site, Grapevine

77401

Regeneron Investigational Site, Bellaire

77478

Regeneron Investigational Site, Sugar Land

77479

Regeneron Investigational Site, Sugar Land

78205

Regeneron Investigational Site, San Antonio

85234

Regeneron Investigational Site, Gilbert

89052

Regeneron Investigational Site, Henderson

89144

Regeneron Investigational Site, Las Vegas

90025

Regeneron Investigational Site, Los Angeles

90067

Regeneron Investigational Site, Los Angeles

90277

Regeneron Investigational Site, Redondo Beach

90404

Regeneron Investigational Site, Santa Monica

91320

Regeneron Investigational Site, Thousand Oaks

92056

Regeneron Investigational Site, Oceanside

92123

Regeneron Investigational Site, San Diego

92354

Regeneron Investigational Site, Loma Linda

92653

Regeneron Investigational Site, Laguna Hills

92663

Regeneron Investigational Site, Newport Beach

92708

Regeneron Investigational Site, Fountain Valley

95661

Regeneron Investigational Site, Roseville

97239

Regeneron Investigational Site, Portland

98004

Regeneron Investigational Site, Bellevue

90266-2911

Regeneron Investigational Site, Manhattan Beach

92506-0174

Regeneron Investigational Site, Riverside

06519

Regeneron Investigational Site, New Haven

30342-1703

Regeneron Investigational Site, Atlanta

30060-1047

Regeneron Investigational Site, Marietta

02169

Regeneron Investigational Site, Quincy

65212-0001

Regeneron Investigational Site, Columbia

08724

Regeneron Investigational Site, Brick

08520

Regeneron Investigational Site, East Windsor

08820

Regeneron Investigational Site, Edison

08854

Regeneron Investigational Site, Piscataway

11373-4831

Regeneron Investigational Site, Elmhurst

10012-1354

Regeneron Investigational Site, New York

10467-2401

Regeneron Investigational Site, The Bronx

29420-4211

Regeneron Investigational Site, North Charleston

L8L 8E7

Regeneron Investigational Site, Hamilton

L3P 1X2

Regeneron Investigational Site, Markham

K1G 6G6

Regeneron Investigational Site, Ottawa

K9J 5K2

Regeneron Investigational Site, Peterborough

M5G 1E2

Regeneron Investigational Site, Toronto

G1V 4X7

Regeneron Investigational Site, Québec

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT03428646 - Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD) | Biotech Hunter | Biotech Hunter